ArticleNeurocritical care2016
Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage.
Article in Neurocritical care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Does duration of nimodipine therapy impact outcome in aneurysmal subarachnoid hemorrhage: systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Efficacy and safety of intraventricular nimodipine in patients with aneurysmal subarachnoid hemorrhage compared to oral nimodipine: a systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Phase 1, randomized, crossover study comparing intravenous GTX-104 to oral nimodipine in healthy human subjects.PloS one · 2025Trial
- Exploring postictal recovery with acetaminophen or nimodipine: A randomized-controlled crossover trial.Annals of clinical and translational neurology · 2024Trial
- Trial
- Oral Nimodipine in Aneurysmal Subarachnoid Hemorrhage: A Critical Propensity Score-Matched Reevaluation in a Contemporary Cohort.Neurology and therapy · 2026Article
- Admission laboratory parameters for early risk stratification after aneurysmal subarachnoid hemorrhage: a machine learning analysis of real-world data.Brain & spine · 2026Article
- Impact of Nimodipine-Induced Blood Pressure Reductions on Cerebral Autoregulation and Functional Outcome After Aneurysmal Subarachnoid Hemorrhage.Neurocritical care · 2025Observational
- Comparison of Clazosentan and Nimodipine on Vasospasm and Vasospasm-Related Outcomes after Aneurysmal Subarachnoid Hemorrhage : A Post-hoc Propensity Score-Matched Analysis of Six Randomized Clinical Trials.Journal of Korean Neurosurgical Society · 2025Article
- Article
- Switching Off Vascular MAPK Signaling: A Novel Strategy to Prevent Delayed Cerebral Ischemia Following Subarachnoid Hemorrhage.Translational stroke research · 2025Review
- Effects of early high-dose vasopressor administration in patients after aneurysmal subarachnoid hemorrhage: a retrospective single-center study.Acta neurochirurgica · 2025Article
- Enteral Nimodipine in Aneurysmal Subarachnoid Hemorrhage: Real-World Application and Challenges.The Canadian journal of hospital pharmacy · 2025Article
- Ultrasound-Induced Release Profile of Nimodipine from Drug-Loaded Block Copolymers after Singular vs. Repeated Sonication: In Vitro Analysis in Artificial Cerebrospinal Fluid.Brain sciences · 2024Article
- Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics.The pharmacogenomics journal · 2024Article
- Pharmacological Prevention of Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage.Neurocritical care · 2024Review
- The Laboratory Origins of Nimodipine in Cerebral Vasospasm.Neurocritical care · 2024Article
- Risks of nimodipine dose reduction during the high-risk period for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.Neurosurgical review · 2024Article
- Guidelines for the Neurocritical Care Management of Aneurysmal Subarachnoid Hemorrhage.Neurocritical care · 2023Article
- Blood Pressure Changes in Association with Nimodipine Therapy in Patients with Spontaneous Subarachnoid Hemorrhage.Neurocritical care · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of cerebral infarction and poor outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH) is reduced by oral nimodipine but acute effects of the drug may include a significant decrease in mean arterial blood pressure (MAP). A dose reduction or discontinuation of the drug is recommended if recurrent MAP drops occur. The aim of our study was to evaluate the frequency and clinical significance of nimodipine dose modifications in patients suffering from aSAH.
methods270 patients were included in our retrospective analysis of consecutively collected data of patients suffering from aSAH. The local treatment protocol was in accordance to national and international guidelines. Nimodipine was intended to be applied orally with a dosage of 60 mg every 4 h.
resultsOnly 43.6 % of patients eligible for vasospasm prophylaxis with nimodipine received the full daily dose of 60 mg every 4 h. In 28.6 %, the dose had to be reduced by 50 % due to a significant reduction in blood pressure after administration and/or high dose of catecholamines. In 27.7 % of patients, oral administration of the drug was discontinued for the same reason. Dose reduction and discontinuation occurred with a significantly higher frequency in patients in poor clinical condition. Application of the full nimodipine dosage decreased the risk of unfavorable clinical outcome in multivariate analysis (OR 0.895, p = 0.029).
conclusionsOur results show that dose reduction or discontinuation of nimodipine due to changes in MAP occur frequently in clinical routine and may be associated with unfavorable clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.